具有抗肿瘤活性的取代 E-3-(3-吲哚基亚甲基)-1,3-二氢吲哚-2-酮。深入研究对乳腺癌细胞生长的影响。
Substituted E-3-(3-indolylmethylene)-1,3-dihydroindol-2-ones with antitumor activity. In depth study of the effect on growth of breast cancer cells.
机构信息
Dipartimento di Scienze Farmaceutiche, Universita di Bologna, Bologna, Italy.
出版信息
J Med Chem. 2010 Aug 12;53(15):5567-75. doi: 10.1021/jm1007165.
Abstract
The synthesis of new substituted E-3-(3-indolylmethylene)-1,3-dihydroindol-2-ones is reported. The antitumor activity was evaluated according to protocols available at the National Cancer Institute (NCI), Bethesda, MD. Structure-activity relationships are discussed. The action of selected compounds was investigated in MCF-7 breast cancer cells. The ability of these derivatives to inhibit cellular proliferation was accompanied by increased level of p53 and its transcriptional targets p21 and Bax, interference in the cell cycle progression with cell accumulation in the G2/M phase, and activation of apoptosis.
摘要
报告了新型取代的 E-3-(3-吲哚亚甲基)-1,3-二氢吲哚-2-酮的合成。根据马里兰州贝塞斯达的国家癌症研究所 (NCI) 的可用方案评估了抗肿瘤活性。讨论了结构-活性关系。在 MCF-7 乳腺癌细胞中研究了选定化合物的作用。这些衍生物抑制细胞增殖的能力伴随着 p53 及其转录靶标 p21 和 Bax 的水平升高，细胞周期进展受阻，细胞在 G2/M 期积累，以及凋亡激活。
相似文献
1
Substituted E-3-(3-indolylmethylene)-1,3-dihydroindol-2-ones with antitumor activity. In depth study of the effect on growth of breast cancer cells.
J Med Chem. 2010 Aug 12;53(15):5567-75. doi: 10.1021/jm1007165.
2
Substituted E-3-(3-indolylmethylene)1,3-dihydroindol-2-ones with antiproliferative activity. Study of the effects on HL-60 leukemia cells.
Eur J Med Chem. 2014 May 22;79:382-90. doi: 10.1016/j.ejmech.2014.04.004. Epub 2014 Apr 3.
3
Synthesis and antitumor activity of 1,5,6-substituted E-3-(2-chloro-3-indolylmethylene)-1,3-dihydroindol-2-ones.
J Med Chem. 2002 Jun 6;45(12):2666-9. doi: 10.1021/jm011123c.
4
Substituted E-3-(2-chloro-3-indolylmethylene)1,3-dihydroindol-2-ones with antitumor activity. Effect on the cell cycle and apoptosis.
J Med Chem. 2007 Jul 12;50(14):3167-72. doi: 10.1021/jm070235m. Epub 2007 Jun 9.
5
Antitumor activity of substituted E-3-(3,4,5-trimethoxybenzylidene)-1,3-dihydroindol-2-ones1.
J Med Chem. 2006 Nov 16;49(23):6922-4. doi: 10.1021/jm0607808.
6
Antitumor activity of new substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones and 3-(5-imidazo[2,1-b]thiadiazolylmethylene)-2-indolinones: selectivity against colon tumor cells and effect on cell cycle-related events.
J Med Chem. 2008 Dec 11;51(23):7508-13. doi: 10.1021/jm800827q.
7
Cytotoxic activities of substituted 3-(3,4,5-trimethoxybenzylidene)-1,3-dihydroindol-2-ones and studies on their mechanisms of action.
Eur J Med Chem. 2013 Jun;64:603-12. doi: 10.1016/j.ejmech.2013.03.033. Epub 2013 Apr 3.
8
Substituted E-3-(2-Chloro-3-indolylmethylene)1,3-dihydroindol-2-ones with antitumor activity.
Bioorg Med Chem. 2004 Mar 1;12(5):1121-8. doi: 10.1016/j.bmc.2003.11.031.
9
Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy.
Curr Cancer Drug Targets. 2010 May;10(3):319-31. doi: 10.2174/156800910791190229.
10
Spirooxindole-derived morpholine-fused-1,2,3-triazoles: Design, synthesis, cytotoxicity and apoptosis inducing studies.
Eur J Med Chem. 2015 Sep 18;102:413-24. doi: 10.1016/j.ejmech.2015.08.017. Epub 2015 Aug 12.
引用本文的文献
1
Mechanistic insight and structure activity relationship of isatin-based derivatives in development of anti-breast cancer agents.
Mol Cell Biochem. 2024 May;479(5):1165-1198. doi: 10.1007/s11010-023-04786-0. Epub 2023 Jun 17.
2
Synthesis and Biological Evaluation of New Bis-Indolinone Derivatives Endowed with Cytotoxic Activity.
Molecules. 2021 Oct 16;26(20):6277. doi: 10.3390/molecules26206277.
3
Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)--substituted-hydrazinecarbothioamides.
Med Chem Res. 2013;22(4):2014-2022. doi: 10.1007/s00044-012-0184-x. Epub 2012 Aug 26.
本文引用的文献
1
Antitumor activity and COMPARE analysis of bis-indole derivatives.
Bioorg Med Chem. 2010 May 1;18(9):3004-11. doi: 10.1016/j.bmc.2010.03.063. Epub 2010 Mar 28.
2
Caspases and kinases in a death grip.
Cell. 2009 Sep 4;138(5):838-54. doi: 10.1016/j.cell.2009.08.021.
3
Targeting PI3K signalling in cancer: opportunities, challenges and limitations.
Nat Rev Cancer. 2009 Aug;9(8):550-62. doi: 10.1038/nrc2664.
4
Cytotoxicity of methoctramine and methoctramine-related polyamines.
Chem Biol Interact. 2009 Oct 30;181(3):409-16. doi: 10.1016/j.cbi.2009.06.015. Epub 2009 Jul 1.
5
p21 in cancer: intricate networks and multiple activities.
Nat Rev Cancer. 2009 Jun;9(6):400-14. doi: 10.1038/nrc2657.
6
Tumour cell survival signalling by the ERK1/2 pathway.
Cell Death Differ. 2009 Mar;16(3):368-77. doi: 10.1038/cdd.2008.148. Epub 2008 Oct 10.
7
Regulation of programmed cell death by the p53 pathway.
Adv Exp Med Biol. 2008;615:201-21. doi: 10.1007/978-1-4020-6554-5_10.
8
Substituted E-3-(2-chloro-3-indolylmethylene)1,3-dihydroindol-2-ones with antitumor activity. Effect on the cell cycle and apoptosis.
J Med Chem. 2007 Jul 12;50(14):3167-72. doi: 10.1021/jm070235m. Epub 2007 Jun 9.
9
Transcription-independent pro-apoptotic functions of p53.
Curr Opin Cell Biol. 2005 Dec;17(6):631-6. doi: 10.1016/j.ceb.2005.09.007. Epub 2005 Oct 13.
10
Substituted E-3-(2-Chloro-3-indolylmethylene)1,3-dihydroindol-2-ones with antitumor activity.
Bioorg Med Chem. 2004 Mar 1;12(5):1121-8. doi: 10.1016/j.bmc.2003.11.031.
Zotero 插件